Featured - Page 4 of 5 - Precision Biologics

25MarMarch 25, 2021

Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress, USA

Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress,...

01DecDecember 1, 2020

Dr. Philip M. Arlen gives scientific presentation at World Vaccine & Immunotherapy Congress West Coast...

06OctOctober 6, 2020

Dr. Philip M Arlen, MD, President and CEO is Presenting the Following Talk at the...

25AugAugust 25, 2020

NIH Intramural Research Program (IRP) highlights Precision Biologics NEO-201 monoclonal antibody.

15JulJuly 15, 2020

Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have...

22JunJune 22, 2020

Precision Biologics along with our collaborators at the National Cancer Institute present research data using...

30AprApril 30, 2020

Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...

07FebFebruary 7, 2020

NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....

23JanJanuary 23, 2020

This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and...

16JanJanuary 16, 2020

The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of...